Gramercy Funds Management Boosted Its Holding in Valeant Pharmaceuticals Intl (Call) (VRX) by $1.49 Million as Market Value Declined; Franklin Street Advisors Trimmed Position in Pepsico (PEP) by $5.85 Million as Stock Declined

May 21, 2018 - By Michael Collier

PepsiCo, Inc. (NASDAQ:PEP) Logo

Gramercy Funds Management Llc increased its stake in Valeant Pharmaceuticals Intl (Call) (VRX) by 295.26% based on its latest 2017Q4 regulatory filing with the SEC. Gramercy Funds Management Llc bought 74,700 shares as the company’s stock declined 28.77% with the market. The hedge fund held 100,000 shares of the health care company at the end of 2017Q4, valued at $2.08M, up from 25,300 at the end of the previous reported quarter. Gramercy Funds Management Llc who had been investing in Valeant Pharmaceuticals Intl (Call) for a number of months, seems to be bullish on the $7.69B market cap company. The stock decreased 0.54% or $0.12 during the last trading session, reaching $22.02. About 3.80 million shares traded. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has risen 42.00% since May 21, 2017 and is uptrending. It has outperformed by 30.45% the S&P500.

Franklin Street Advisors Inc decreased its stake in Pepsico Incorporated (PEP) by 83.07% based on its latest 2017Q4 regulatory filing with the SEC. Franklin Street Advisors Inc sold 49,187 shares as the company’s stock declined 9.24% with the market. The hedge fund held 10,026 shares of the consumer non-durables company at the end of 2017Q4, valued at $1.20 million, down from 59,213 at the end of the previous reported quarter. Franklin Street Advisors Inc who had been investing in Pepsico Incorporated for a number of months, seems to be less bullish one the $140.85B market cap company. The stock increased 1.88% or $1.8298 during the last trading session, reaching $99.3398. About 4.53 million shares traded. PepsiCo, Inc. (NYSE:PEP) has declined 3.75% since May 21, 2017 and is downtrending. It has underperformed by 15.30% the S&P500.

More notable recent Valeant Pharmaceuticals International, Inc. (NYSE:VRX) news were published by: Benzinga.com which released: “Steve Sosnick’s Valeant Options Trade” on May 04, 2018, also Seekingalpha.com with their article: “Valeant to refinance existing credit deal” published on May 10, 2018, Seekingalpha.com published: “Valeant: Much Ado About Nothing” on May 21, 2018. More interesting news about Valeant Pharmaceuticals International, Inc. (NYSE:VRX) were released by: Seekingalpha.com and their article: “Tracking John Paulson’s Paulson & Co. Portfolio – Q1 2018 Update” published on May 18, 2018 as well as Seekingalpha.com‘s news article titled: “Valeant: An Edge Into Earnings” with publication date: April 24, 2018.

Among 28 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 8 have Buy rating, 5 Sell and 15 Hold. Therefore 29% are positive. Valeant Pharmaceuticals Intl had 169 analyst reports since July 21, 2015 according to SRatingsIntel. Barclays Capital downgraded Valeant Pharmaceuticals International, Inc. (NYSE:VRX) rating on Monday, March 21. Barclays Capital has “Equal-Weight” rating and $34 target. Deutsche Bank initiated the shares of VRX in report on Tuesday, September 20 with “Hold” rating. The rating was maintained by BTIG Research on Thursday, May 11 with “Neutral”. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Hold” rating given on Tuesday, October 3 by Canaccord Genuity. Stifel Nicolaus maintained the shares of VRX in report on Wednesday, March 16 with “Buy” rating. The stock has “Overweight” rating by Morgan Stanley on Wednesday, August 17. The company was maintained on Wednesday, January 17 by BTIG Research. H.C. Wainwright maintained the shares of VRX in report on Tuesday, January 16 with “Hold” rating. The rating was downgraded by Goldman Sachs on Monday, November 2 to “Neutral”. As per Tuesday, February 14, the company rating was maintained by RBC Capital Markets.

Since March 8, 2018, it had 3 insider buys, and 0 sales for $876,370 activity. 30,000 Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shares with value of $481,500 were bought by PAPA JOSEPH C. Herendeen Paul bought $241,470 worth of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Tuesday, March 13.

Investors sentiment decreased to 0.97 in Q4 2017. Its down 0.02, from 0.99 in 2017Q3. It fall, as 51 investors sold VRX shares while 74 reduced holdings. 54 funds opened positions while 67 raised stakes. 169.66 million shares or 0.12% less from 169.87 million shares in 2017Q3 were reported. Wolverine Asset Management Ltd Liability invested in 0.1% or 455,646 shares. Ajo Limited Partnership holds 0.01% or 160,537 shares. Axa stated it has 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Creative Planning has 0.03% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Tokio Marine Asset Ltd holds 95,900 shares. Nomura reported 5.57M shares stake. Sumitomo Mitsui Trust Hldgs Inc has 0.01% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Hexavest holds 0.13% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 545,703 shares. Comerica National Bank holds 18,784 shares. The New York-based Gabelli Funds Ltd Company has invested 0.01% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Bridgewater Assoc Lp holds 41,855 shares or 0.01% of its portfolio. Webster National Bank & Trust N A accumulated 300 shares. Tci Wealth Advisors accumulated 0% or 25 shares. Tobam holds 0.67% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 736,718 shares. Stratos Wealth Prtn Ltd reported 3,061 shares.

Franklin Street Advisors Inc, which manages about $2.06B and $668.49 million US Long portfolio, upped its stake in Eog Resources Inc (NYSE:EOG) by 18,015 shares to 100,833 shares, valued at $10.88M in 2017Q4, according to the filing. It also increased its holding in Protagonist Therapeutics Inc by 30,000 shares in the quarter, for a total of 46,700 shares, and has risen its stake in Dowdupont Inc.

Investors sentiment decreased to 0.86 in 2017 Q4. Its down 0.08, from 0.94 in 2017Q3. It turned negative, as 63 investors sold PEP shares while 712 reduced holdings. 122 funds opened positions while 542 raised stakes. 958.76 million shares or 0.63% less from 964.87 million shares in 2017Q3 were reported. Essex Financial owns 30,648 shares. Spectrum Asset Mgmt Incorporated (Nb Ca) invested 0.27% of its portfolio in PepsiCo, Inc. (NASDAQ:PEP). 12,685 were accumulated by Gould Asset Mgmt Ltd Liability Ca. Cheviot Value Ltd reported 22,891 shares. Marco Inv Management Ltd Liability holds 0.07% or 4,083 shares. 22,344 are held by Northstar Gp. Eagle Asset Management stated it has 0.16% in PepsiCo, Inc. (NASDAQ:PEP). Round Table Ltd Liability Com holds 1,677 shares. The Missouri-based Argent Cap Limited Liability Corp has invested 0.82% in PepsiCo, Inc. (NASDAQ:PEP). The California-based Rbf Limited Liability Co has invested 3.18% in PepsiCo, Inc. (NASDAQ:PEP). Sns Fincl Ltd Llc has invested 0.11% in PepsiCo, Inc. (NASDAQ:PEP). Rhumbline Advisers, Massachusetts-based fund reported 2.55M shares. Rmsincerbeaux Capital Lc reported 0.22% of its portfolio in PepsiCo, Inc. (NASDAQ:PEP). Welch Cap Prtnrs Limited Com Ny has invested 3.26% of its portfolio in PepsiCo, Inc. (NASDAQ:PEP). Amf Pensionsforsakring Ab has 1.85% invested in PepsiCo, Inc. (NASDAQ:PEP).

Analysts await PepsiCo, Inc. (NASDAQ:PEP) to report earnings on July, 10. They expect $1.52 earnings per share, up 1.33% or $0.02 from last year’s $1.5 per share. PEP’s profit will be $2.16 billion for 16.34 P/E if the $1.52 EPS becomes a reality. After $0.96 actual earnings per share reported by PepsiCo, Inc. for the previous quarter, Wall Street now forecasts 58.33% EPS growth.

Another recent and important PepsiCo, Inc. (NASDAQ:PEP) news was published by Prnewswire.com which published an article titled: “PepsiCo, Inc. to Withdraw Chicago Stock Exchange Listing; Retains Nasdaq Listing” on May 18, 2018.

Among 22 analysts covering PepsiCo (NYSE:PEP), 8 have Buy rating, 1 Sell and 13 Hold. Therefore 36% are positive. PepsiCo had 69 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Buy” rating by Susquehanna on Thursday, July 6. The stock has “Neutral” rating by Goldman Sachs on Wednesday, June 29. On Tuesday, July 21 the stock rating was initiated by Sterne Agee CRT with “Buy”. Jefferies maintained the shares of PEP in report on Thursday, January 4 with “Hold” rating. Deutsche Bank maintained the shares of PEP in report on Friday, July 8 with “Buy” rating. The stock of PepsiCo, Inc. (NASDAQ:PEP) earned “Buy” rating by Stifel Nicolaus on Wednesday, October 7. The company was maintained on Tuesday, September 5 by RBC Capital Markets. On Friday, September 8 the stock rating was downgraded by Credit Suisse to “Neutral”. The firm has “Hold” rating by Stifel Nicolaus given on Thursday, October 12. As per Thursday, October 5, the company rating was maintained by Credit Suisse.

PepsiCo, Inc. (NASDAQ:PEP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Michael Collier

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts